Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Invitation to Latour’s presentation of the half year report for 2020

Latour will publish the interim report for the second quarter on 20 August, 2020 at 08.30 AM (CEST). President and CEO Johan Hjertonsson will present the report and answer to questions together with CFO Anders Mörck on the same day at 10.00 AM (CEST) in a webcasted telephone conference. To participate in the meeting and be able to ask questions, please call +46 (0)8 505 583 58To follow the webcast please use the link: https://onlinexperiences.com/Launch/QReg/ShowUUID=5F0B3FD3-8873-451B-875D-FD02D4A6E504 Göteborg, August 13, 2020 INVESTMENT AB LATOUR (PUBL)Johan Hjertonsson,

Fortum initiates an Environmental Impact Assessment procedure for Loviisa nuclear power plant

FORTUM CORPORATION PRESS RELEASE 13.8.2020   Fortum [Power and Heat Oy] has initiated an Environmental Impact Assessment procedure (EIA procedure) for the Loviisa nuclear power plant. The procedure will assess the environmental impacts of a potential extension of the operation of the power plant or, alternatively, the decommissioning of the power plant, as well as the environmental impacts of the final disposal facility for low- and intermediate-level waste.  “Loviisa power plant’s current operating licenses are valid until the end of 2027 and 2030. In this procedure, we will

Invitation to Tobii’s Earnings Call Following the Second Quarter of 2020

Tobii AB plans to publish the interim report for the period January 1-June 30, 2020 on August 19 at 7.30 a.m. CET. Following this report, at 10.00 a.m. CET, Tobii will host a conference call with web cast presentation for investors, analysts and media. Tobii’s President and CEO Henrik Eskilsson and CFO Johan Wilsby will present and comment on the report. After the presentation, there will be time for questions. The presentation will be held in English. Conference call · Time: Wednesday August 19, 2020, 10.00 a.m. CET · Phone numbers: Sweden                          +46 (0)

Contract for CSV Normand Vision with Ocean Installer

Solstad Offshore ASA has been awarded a contract with Ocean Installer for the CSV Normand Vision. The contract commences in 1Q and the firm and optional periods covers the majority of 2021. Normand Vision is a high capacity Construction Support Vessel designed and built for installation of Subsea Structures, Umbilicals, Risers and Flowlines (SURF). The vessel was delivered in 2014 and has worked for Ocean Installer most of the time since then.   Skudeneshavn, August 13[th], 2020 ContactsLars Peder Solstad CEO, at +47 91 31 85 85Kjetil Ramstad CFO, at +47 90 75 94 89 Solstad

Höegh LNG: Webcast/Q&A session details for the second quarter and first half of 2020 financial results

Hamilton, Bermuda, 13 August 2020 - Höegh LNG Holdings Ltd. ("Höegh LNG") will release its financial results for the quarter and half year ended 30 June 2020 on Thursday 20 August 2020 at 07:00 am CET. In connection with this, Höegh LNG will hold a webcast at 09:00 am CET which will immediately be followed by a Q&A session. The webcast can be accessed through the following channels:   · · Via "Investor relations" on Höegh LNG's website www.hoeghlng.com, or the following link: https://channel.royalcast.com/webcast/hegnarmedia/20200820_5/ · By dialling +47 2100 2610 (Oslo), +44 (0)

Invitation to a conference call and webcast by Isofol in connection with the entered license agreement with Solasia

GOTHENBURG, Sweden, August 13, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) has today announced that it entered into a license agreement with Solasia Pharma K.K (“Solasia”) (TSE: 4597), to develop and commercialize Isofol’s proprietary late-stage drug candidate arfolitixorin in Japan. In connection with this, Isofol invites investors, analysts and media to a conference call and webcast on August 13, 2020 at 11:00 (CEST).The presentation will be held by CEO Ulf Jungnelius in English and will conclude with a Q&A session. Questions can be asked

2020 Bulkers Ltd. (2020) – Commercial update and key information relating to the dividend for July 2020.

Hamilton, Bermuda, August 13, 2020 Commercial update: In July 2020, the Company achieved average time charter equivalent earnings of approximately US$23,200 per day, gross. The Company’s two vessels trading on index-linked time charter earned approximately US$35,200 per day, gross, including average daily scrubber benefits of approximately US$1,400 per day. The Company’s six vessels trading on fixed time charter earned approximately US$19,300 per day, gross, including average daily scrubber benefits of approximately US$1,400 per day for two of the vessels. The Baltic 5TC Capesize

Evolution selected for PointsBet US Live Casino rollout

[PR] Evolution Gaming, leading provider of Live Casino solutions, announced today that it has been selected by PointsBet, a premier global sportsbook operator, for its rollout of Live Casino services in the US online gambling market.Originally founded in Australia, PointsBet is currently operational in New Jersey, Indiana, and Iowa, offering both online and land-based sports betting. PointsBet entered the US market in July 2018 when it gained a commercial licence to operate as an online corporate bookmaker in New Jersey and commenced taking bets in the Garden State in January 2019. Since

Isofol enters licensing agreement with Solasia to develop and commercialize arfolitixorin in Japan

GOTHENBURG, Sweden, August 13, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) today announced that it entered into a license agreement with Solasia Pharma K.K (“Solasia”) (TSE: 4597), a specialized oncology company headquartered in Japan, to develop and commercialize Isofol’s proprietary late-stage drug candidate arfolitixorin in Japan. Under the terms of the agreement, Isofol will receive a total amount of ~$ 100 million* (SEK 890 million*) as upfront, development, regulatory and sales-based milestone payments and clinical development cost. In

Basware appoints Mogens Pedersen Chief Technology Officer and Perttu Nihti Chief Product Officer

Basware Corporation, stock exchange release, August 13, 2020 at 9.30 am EESTMogens Pedersen has been appointed Chief Technology Officer and Perttu Nihti has been appointed Chief Product Officer at Basware. The appointments are effective as of September 1, 2020 when both will become members of the Executive Team, reporting to the CEO, Klaus Andersen. Mr. Pedersen joins Basware from SimCorp, a leading provider of integrated investment management solutions, where he worked in multiple senior leadership roles for the last 26 years, most recently as Head of the Cloud Centre of Excellence at

Mentice publishes the company’s interim report for the period January–June 2020

Solid performance for the quarter and the first half of the year despite the effects of the pandemic  Second quarter 2020 · Net sales amounted to 24.3 (32.4) MSEK. · Operating income for the period before depreciations (EBITDA) totalled -12.0 (-10.1) MSEK. · Net income for the period amounted to -11.1 (-10.8) MSEK. · Earnings per share (EPS) was -0.46 (-0.59) SEK. · Order intake amounted to 28.4 (34.9) MSEK. · Cash flow from operating activities totalled 15.2 (-0.8) MSEK. January-June 2020 · Net sales for the first half of the year amounted to 58.1 (59.8)

2020 Bulkers Ltd. (2020) - Results for the second quarter and the first half of 2020

Hamilton, Bermuda, August 13, 2020 2020 Bulkers Ltd (2020) (“2020 Bulkers” or the “Company”), today announced its unaudited financial and operating results for the three and six months ended June 30, 2020. Key events during the second quarter of 2020 · The Company reported net profit of US$2.4 million and EBITDA of US$6.9 million for the second quarter of 2020. · Achieved average time charter equivalent earnings of approximately US$19,100, per day, gross. · Entered into interest swap arrangements for a notional amount of approximately US$177 million, effectively

Musti Group Plc: Announcement of a change in shareholding according to Chapter 9, Section 10 of the Finnish Securities Market Act

Stock Exchange Release 13 August 2020, at 9:15 a.m.Musti Group Plc (the "Company") has today received a notification in accordance with the Chapter 9, Section 10 of the Finnish Securities Market Act from EQT Mid Market GP B.V. ("EQT"), according to which Millan Holding S.à.r.l., a company ultimately owned by EQT and its co-investors, has sold a total number of 6,201,607 Company's shares in an accelerated book-building process (the "Share Sale"). In connection with the Share Sale, EQT's indirect holding of the shares and votes of the Company has decreased below 10 percent. As a result of the

Flexion Mobile launches Battle Warship from Special Gamez

The Top Tier game is now live in all Flexion key channelsLONDON, 13th of August, 2020 – Flexion Mobile Plc (Nasdaq: FLEXM), the Android games distribution company today announced that it has launched Battle Warship Naval Empire. In July, the top tier game generated USD 3 million net revenue in Google Play according to data analyst Sensor Tower. The studio behind this successful game was recently acquired by the US NASDAQ listed company iQIYI, also known as Netflix of China. The game is now live on Amazon, Huawei, ONE Store and Samsung "It is really great to see how we are ramping up our

Half-Yearly Report January – June 2020

April – June in brief · Net sales rose by 35 percent to SEK 15,490 (11,509) thousand. Adjusted for acquired sales, growth rose by 11% to SEK 12,714 thousand. · Gross profit/loss improved by SEK 978 thousand and totaled SEK 13,146 (12,168) thousand. · Operating result before depreciation and amortization (EBITDA) totaled SEK -38 (2,390) thousand and was negatively impacted by non-recurring items for acquisitions and restructuring costs of SEK 1 million. · Operating result totaled SEK -1,291 (1,628) thousand. · Comprehensive income for the period totaled SEK -3,124 (1,380)

Invitation to presentation of Immunovia´s interim report January – June 2020 on August 20, 2020

LUND (Sweden) – Immunovia invites to a teleconference (in English) for investors, analysts and media on Thursday, August 20[th], 2020 at 16:30 CET. Immunovia will publish the company’s interim report on August 20[th], 2020 at 16:00 CET. Mats Grahn, CEO will present Immunovia and comment on the interim report for the period January – June 2020 followed by a Q&A session. Please call in a few minutes in advance. To attend, please dial-in at one of the numbers below and provide the conference code Immunovia to the operator: Conference Numbers: Sweden: +46 (0) 8 50520424 United

Kamux Corporation’s Half Year Financial Report for January 1 - June 30, 2020

Kamux Corporation                Half Year Financial Report                           August 13, 2020 at 09:00 Kamux Corporation’s Half Year Financial Report for January 1 - June 30, 2020 Kamux’s Business Model Proved its Strength in an Exceptional Situation - Profitability Improved, Revenue Declined by -4.3% The figures in parentheses refer to the comparison period, i.e. the same period in the previous year, unless stated otherwise. April-June in brief - Revenue decreased by -4.3%, totaling EUR 150.5 million (157.3) - Gross profit increased by 2.4% to EUR 20.6 million (20.

LeoVegas AB Q2: Quarterly report 1 April - 30 June 2020

“The strong EBITDA growth clearly illustrates the scalability of our business model” – Gustaf Hagman, Group CEO second quarter 2020: 1 april–30 june ·Revenue increased by 17% to EUR 110.7 m (94.4). Organic growth in local currencies was 19%. ·EBITDA was EUR 23.0 million (15.1), corresponding to an EBITDA margin of 20.8% (16.0%) and a growth of 53 %. ·The number of depositing customers was 434,453 (350,298), an increase of 24%. ·Earnings per share were EUR 0.14 (0.08) before and after dilution, while adjusted earnings per share were EUR 0.19 (0.11).

Sivers IMA completes share issue of 555 262 new shares

The Board of Directors of Sivers IMA Holding AB (“Sivers IMA” or “the Company”) has today, based on the authorisation resolved by the Annual General Meeting held on 19 May 2020, resolved on a set-off share issue of 555,262 shares (corresponding to approximately 0.39 percent of the number of outstanding shares and votes in the Company after dilution). The subscription price amounts to SEK 22.80 per share, corresponding to approximately 92,5 percent of the volume-weighted price paid for the Company's share on Nasdaq First North Growth Market during the period from 10 August 2020 to 12 August

Interim Report January – June 2020

Second quarter 2020 · Net sales amounted to SEK 244.7 million (222.3), an increase of 10% (excluding foreign exchange effects, 8%). Product sales, net sales excluding royalty revenues, amounted to SEK 238.2 million (218.4), an increase of 9% (excluding foreign exchange effects, 7%). · Net sales in the Paediatrics segment reached SEK 199.2 million (181.1), an increase of 10%.  · Net sales in the Adult Health segment amounted to SEK 44.4 million (40.9), an increase of 8%.  · Operating expenses amounted to SEK 84.2 million (84.9), a decrease of 1%. · Operating profit increased

Intensive change management during the quarter

Acroud AB (publ) has had a stable quarter marked by intensive change management where restructuring, refinancing and a change of name for the business have been carried out at a rapid pace to create conditions for future success and growth.Acroud AB (publ) has had a stable quarter marked by intensive change management where restructuring, refinancing and a change of name for the business have been carried out at a rapid pace to create conditions for future success and growth.SECOND QUARTER 2020   · Revenue amounted to EUR 3,567 (3,497) thousand. · EBITDA amounted to EUR 1,499 (2,024)

ContextVision’s second quarter sees multiple product releases including digital pathology debut

STOCKHOLM – Aug 13, 2020 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, today reports a progressive second quarter. INIFY® Prostate Screening – the company’s first decision support tool in a planned digital pathology portfolio – was granted CE-mark status, paving the way for a strong entry into the fast-growing digital pathology market. In addition, the company continues to spearhead the image enhancement market with its new next-generation ultrasound product, Rivent®. “It’s been a very progressive quarter with multiple

Strong momentum across all strategic brands with 25% growth in the first half of 2020

HIGHLIGHTS · Revenue reached DKK 8,934 million in the first six months of 2020, a growth of 5% (5% in local currencies) compared to 2019. Excluding sales from Onfi[®], total revenue grew by 10% · Revenue of Abilify Maintena[®] increased 24% to DKK 1,176 million (23% in local currencies) · Revenue of Brintellix[®]/Trintellix[®] increased 21% to DKK 1,575 million (21% in local currencies) · Revenue of Northera[®] increased 19% to DKK 1,202 million (16% in local currency) · Revenue of Rexulti[®]/Rxulti[®] increased 35% to DKK 1,393 million (32% in local currencies)

Nixu Corporation's Half-Year Financial Report 2020: Growth of +14% During Challenging Times

Nixu CorporationStock Exchange Release on August 13, 2020 at 8:30 AM EESTThis release is a summary of the Nixu Corporation’s January 1 – June 30, 2020 Half-Year Financial Report. The complete report is attached to this release as a pdf-file. It is also available on the company website at https://www.nixu.com/H12020. Highlights for January–June 2020 · Revenue: EUR 29,218 thousand (25,685), change +14%. Organic growth: +5%. Managed continuous services grew by +37% representing 18% of revenue. · EBITDA: EUR 147 thousand (1,975), share of revenue: 1% (8%). · Adjusted EBITDA: EUR

There are no items matching the current filter
There are no more items matching the current filter
Back to top